Case File
efta-efta00684232DOJ Data Set 9OtherFrom: Terje Rod-Larsen
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00684232
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Terje Rod-Larsen
To: Jeffrey Epstein <[email protected]>
Subject: Fwd: Alzheimers
Date: Thu, 30 Jan 2014 12:53:40 +0000
Sent from my iPhone
Begin forwarded message:
From: Walter Kemp <kemp@lpharg>
Date: January 27, 2014 at 7:32:15 PM GMT+1
To: Terje Rod-Larsen
Cc: Camilla Reksten-Monsen
Subject: Fw: Alzheimers
Terje,
I hope this information on Alzheimer's can be helpful.
Walter
Original Message
From: Andrea Pfeifer [mailto:
Sent: Sunday, January 26, 2014 03:38 AM Eastern Standard Time
To: Walter Kemp
Subject: RE: Alzheimers
Dear Walter,
Really nice to meet you.
The drug, an Anti-Abeta antibody (Anti-Plaues,) is the first drug in a preventive AD study and runs under the
name of Crenezumab. This study is supported by NIH. There are other studies on the same molecule together
with Genentech, i.e. phase 2 studies of efficacy and biomarkers.
You will find a lot of information on our web or Internet.
Please let me know if you have specific questions and I am happy to provide you the answers.
Best
Andrea
Prof. Andrea Pfeifer
CEO
EFTA00684232
AC Immune SA
EPFL Innovation Park (please note our new address)
Building B
CH-1015 Lausanne
Phone: +41 21 693 91 23
Mobile:
Fax:
+41 21
E-mail:
693 91 20
This e-mail message is confidential and for use of the intended recipient(s) only. This communication may
contain information that is proprietary, privileged or confidential or otherwise legally exempt from
disclosure. Unauthorized use or treatment of all or part of this message is strictly prohibited. Unintended
recipients: please notify the sender and delete the original message, any attachments and any copies from your
computer and back-up system immediately. Thank you.
Original Message
From: Walter Kemp
Sent: 24 January 2014 14:18
To: Andrea Pfeifer
Subject: Alzheimers
Dear Dr. Pfeifer,
We met briefly on the train yesterday on the way to Davos.
You mentioned that your company had produced a drug to counter-act Alzheimers. Could you give me its
name?
Thanks very much and all the best with your important work.
Sincerely,
Walter Kemp (Canadian, based in Vienna)
International Peace Institute
EFTA00684233
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Phone
+41 21 693 91 23Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.